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Abstract
The paper reviews evidence that before any change in diabetics’ fundi, changes occur to blood flow, ERG and visual functions.
In the case of colour vision and contrast sensitivity, the changes are partially reversed by breathing oxygen, and therefore are the
result of retinal hypoxia. There are also other evidences that hypoxia is a major factor in the development of diabetic retinopathy
(DR). Therefore in diabetics with early retinopathy, but normal photopic vision, functional disturbance might appear in dark
adaptation, since in such circumstances, (as shown by Linsenmeier and his colleagues) the already low retinal PO2 markedly
decreases. This hypothesis has been tested and results consistent with the hypothesis (and with a number of older reports) have
been obtained. The significance of this finding to early DR is discussed, and a mechanism suggested whereby prolonged periods
of hypoxia during dark adaptation could generate changes in retinal capillaries. Such periods occur each night, and their
elimination in diabetics could be therapeutic. © 1998 Elsevier Science Ltd. All rights reserved.
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1. Introduction
In the briefest summary, diabetic retinopathy (DR) is
considered basically a vasculopathy. The pericytes,
basement membrane and the endothelial cells of retinal
capillaries are first to show histological degenerative
changes [1–3]. The resulting reduction in vessel diame-
ter, coupled with rheological changes, is thought to lead
to the production of microaneurysms, capillary
dropout, leakage from vessel walls and the pattern of
local hypoxia that is seen clinically [4]. Once tissue
damage has occurred, secondary processes exaggerate
and continue the damage, which may progress (in man
and in experimental animals) even if the diabetes is
cured by pancreatic transplantation [5,6].
Long before the retinal clinical signs of DR appear,
there is evidence of loss of function: there are ERG
changes [7–10]; colour vision changes [11–14]; reduc-
tion of contrast sensitivity [15]; alteration in dark adap-
tation [16–21] and reductions in retinal blood flow
[22,23].
As the clinical condition increases in severity, various
other manifestations can be seen (cotton wool spots,
hard exudates, flame haemorrhages) and the pathologi-
cal changes to blood vessels are accompanied by
changes in the RPE. These are associated with macular
oedema and maculopathies, which, together with prolif-
erative retinopathy, are the chief immediate causes of
loss of vision [4].
The underlying mechanism of DR is thought to be
the metabolic load placed on retinal cells by the lack of
insulin and the increased level of blood glucose, which
leads to abnormal glycation and glycoxidation of spe-
cific compounds [24,2,25]. The abnormal metabolism
has been investigated in detail, particularly in respect to
the polyol pathway, abnormalities of which may di-
rectly cause damage [26–28]. The role of substances
released from damaged tissues has been investigated
[29,30] and it has been shown that in some cases, the
effects on the RPE are controlled by hypoxia [31].
Although close control of insulin levels may slow the
appearance of DR, laser photocoagulation of the retina
remains the only effective treatment for severe back-
ground retinopathy which otherwise develops into pro-
liferative retinopathy and for some forms of
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maculopathy [32,4]. The benefits of antisorbitol oxi-
dase therapy remain undecided [27].
It has been pointed out [33] that the vascular en-
dothelial and pericyte changes of DR (which initiate
the later progressive retinopathy) only occur in retinal
capillaries. In brain capillaries of diabetics, which oth-
erwise resemble retinal vessels, only thickening of the
basal membrane occurs. Therefore local factor(s) must
be responsible for DR. The purpose of this communi-
cation is to suggest the nature of one local factor, and
thus to provide a linking hypothesis for the develop-
ment of DR.
What is peculiar to retina is of course photorecep-
tors, and particularly the more numerous rods
(120000000 compared to 6000000 cones). Rods have
a uniquely high metabolic rate, demanded by the pro-
cesses which enable them to signal the absorption of
single quanta. The outer limbs are depolarised in
darkness, and hyperpolarise in light. Thus a circulat-
ing ionic ‘dark current’ flows extracellularly between
inner and outer limbs, and the current path is com-
pleted intracellularly [34]. The pumps which maintain
this current turn over the entire cell cytosol ionic con-
tents in a few seconds [35]. Additional unusual fea-
tures of rods include the 10% of the outer limb shed
and resynthesised each day, and the external neuro-
transmitters and internal transmitters that are con-
stantly catabolised and anabolised.
Such a considerable degree of metabolic activity de-
mands a high blood supply. Rods are avascular but
are supplied by the extensive choroidal capillary net-
work. The evidence that oxygen requirements are very
high is that in cats and monkeys, while the PO2 at
Bruch’s membrane approximates to the arterial PO2,
it falls precipitously to very low values in the outer
plexiform layer, despite the richness of the choroidal
vascular supply. The oxygen tension reduces still fur-
ther in dark adaptation. The maximum decrease in
PO2 in darkness (and the trough of the oxygen
profile) occurs about 110 mM from the choroid where
(in dark adapted cats) the tension is approximately
zero [36–40] though it is higher in monkeys [41]. In
darkness, an unusually low PO2 continues into the
retina up to 150 mM from the choroid, because the
rods act as ‘sink’ for oxygen supplied by the retinal
circulation. In light adaptation, the dark current and
the oxygen sink decrease very considerably. Quantita-
tive analysis shows that \50% of all the oxygen is
consumed by the photoreceptors, and that this is
halved in light. Light does not influence the use of
oxygen by the remaining layers of the retina, at least
in monkeys.
We suggest that in diabetes the retinal circulation is
initially embarrassed to the same degree as are other
capillaries and small arterioles, but dark adaptation
imposes additional periods of more profound hypoxia
(at the retinal depths indicated above). It is a conse-
quence of this hypothesis that in persons with back-
ground DR, even if photopic visual function is
unaffected, scotopic function might be abnormal. The
experiments described below were designed to test this
prediction.
If in otherwise normal retina, hypoxia in dark
adaptation can lead to loss of rod function, there is a
further implication. The actual deficit in sensitivity of
rods may well be unimportant, but demonstrates the
hypoxia, which (by a mechanism detailed in Section
4), could allow dark adapted hypoxia to exacerbate
the inner retinal vascular changes, thus contributing
to the DR.
2. Methods
2.1. Subjects
Twenty five normal subjects served as controls for
the dark adaptation procedures. Twenty two were un-
trained students aged 20–30: the remaining were ex-
perienced observers aged 40, 55 and 67. There were
no significant differences between their results and
those of the younger group. All had best corrected
vision of 6:6 or better and no ocular disease. Four
diabetics aged 25–33 were investigated. All had rapid
onset insulin dependent diabetes mellitus (IDDM) in
childhood. They had had no systemic or eye disease
(other than the background DR) They were all under
the supervision of the Diabetic screening service and
the Department of Ophthalmology of St. Thomas’
Hospital, and had had fluorescein angiograms and
clinical examinations in the last six months. All had
best corrected vision of ]6:6. Of these, three had
mild background DR with few microaneurysms only.
The fourth patient had more microaneurysms, and the
fluorescein angiograms showed extensive areas of pe-
ripheral capillary closure. No haemorrhages or exu-
dates were present in any patient, and there was no
maculopathy. The patients had no other evidence of
other eye or retinal disease, and no systemic disease.
All subjects and patients gave informed consent for
the procedures.
2.2. Procedures
Colour and achromatic contrast sensitivity was de-
termined using the systems described previously [42].
A subset of Sloan optotypes were used as stimuli:
these subtended 2° at the pupil. The stimuli were
flashed for 50 ms with a repetition rate of 1 Hz and
appeared against a uniform background. In the case
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of achromatic contrast, the contrast threshold was
defined and determined in the usual way. For coloured
targets, colour contrast was varied along colour confu-
sion axes for protan or tritan axes, and the threshold
expressed as a percentage of the maximum modulation
possible with the given phosphors in terms of the (XY)
primaries introduced by the Committee Internationale
d’Eclairage (CIE). Some of these tests were part of a
standard clinical routine. They were however extended
to mesopic levels, by interposing neutral filters between
the subjects’ eye and the monitor. The filters were
mounted in spectacle frames. In all cases thresholds
were determined by a modified binary search (MOBS)
technique. The diabetics’ results were obtained after a
training session.
Dark adaptation was measured with a stimulator,
powered by light-emitting diodes (LEDs). [43,44]. An
internally reflecting hollow tube was terminated in a
translucent 5 cm internal diameter hemisphere, concave
forward. Different types of LED were mounted facing
forward along the hollow tube, which contained light
diffusers. The interior of the bowl appeared uniformly
bright. When used as an adapting light, the bowl was
placed on the subject’s face to provide a source which
covered 180° of visual angle. (a ‘miniGanzfeld’) The
adapting light appeared orange and had a peak wave-
length 610 nm) giving a retinal illumination of 16000
photopic Td. (1800 sc. Td.) for 120 s. For dark adapta-
tion, the same bowl was placed 57 cm from the eye, and
subtended 5° at 10° in the horizontal nasal field. Blue
LEDs (peak wavelength 440 nm.) were used as stimuli.
For times 5200 s, a computer recorded the times at
which stimuli of preset intensities were seen. Test
flashes were repeated at 1 s intervals. Later in the
experiment, thresholds were obtained by the method of
adjustment by the operator. For normals, each point
represents the average of several subjects’ determina-
tions. The time of the recording thresholds differed by
B10 s. For diabetics, single results are plotted. The
subjects were provided with an appropriate fixation
point. Tests were carried out with the pupil dilated to
\6 mm with 0.5% Tropicamide. Each dark adaptation
curve for every observer was repeated twice. No sys-
tematic variation between trials was observed. Only one
set of results was used for each observer. The effective-
ness of the stimuli was altered by changing both the
luminance of the flashes and their duration (variable
between 1 and 3000 ms.).
The orange light used for pre-adaptation was suffi-
cient for the ‘knee’ on the dark adaptation curve to
occur after 1–3 min. This equipment and regime was
used to obtain dark adaptation which was completed
more rapidly than in the standard clinical test, because
we wished to minimise any change in the diabetic
patients clinical state.
3. Results
3.1. Photopic and mesopic 6isual function
Fig. 1 shows the mean achromatic and colour con-
trast sensitivities of two older normal observers and the
four diabetics as a function of screen illumination. The
right hand points for all observers and test situations
are at full screen luminance, and represent the normal
clinical test we employ. The results for the normals and
diabetics are within the clinic normal limits. The reduc-
tion of screen luminance to 1.78 log cd m2 repre-
sents an extension to low mesopic levels. For
achromatic targets, contrast threshold increased to
nearly 100% with this reduced luminance. There is no
difference between the normals and the diabetics. For
coloured targets, protan discrimination was within
clinic normal results at maximum luminance, and again
no difference was seen between normals and diabetics,
although it was not possible to reduce screen luminance
much below 1 cd m2 and obtain colour discrimina-
tions. The diabetic subjects had slightly worse tritan
colour discrimination than the normals, but the mean
threshold at standard luminance is not significantly
different to the normals. However, at reduced lumi-
nance, (1 cd m2) it was not possible to obtain any
threshold from the diabetics. This result is in agreement
with a number of papers which have shown that in
early DR, there may be a reduction in tritan discrimi-
nation only.
Fig. 1. Achromatic contrast sensitivity (, 
), protan (, ) and
tritan (, ) colour contrast sensitivity in two normals (open sym-
bols) and four diabetic subjects (solid symbols) as a function of mean
luminance of the test screen In all cases, the test objects were a subset
of the Sloan optotypes, subtending 2° at the eye at 1.15 m.
Thresholds were determined with pupils dilated by 1% tropicamide.
The letters appeared for 200 ms at a 1 Hz repetition rate. The short
duration was chosen to reduce any photoreceptor adaptation during
the stimulus. Only in the tritan thresholds is there any suggestion of
a loss of function.
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Fig. 2. Dark adaptation curves obtained in a group of 25 normals ()
and two diabetics. Patient JT (
) only had a few microaneurysms.
Patient NA () had many more microaneurysms and regions of
peripheral capillary drop-out. The preceding light adaptation was by
a 5 cm. diameter bowl apposed to the subjects face (a ‘miniGanzfeld’)
The light was provided by light emitting diodes (peak wavelength 610
nm) giving a retinal illumination of 16000 photopic Td. (1800 sc. Td.)
for 120 s. For dark adaptation, the same bowl was placed 57 cm from
the eye, and subtended 5°. Blue LEDs (peak wavelength 440 nm.)
were used as stimuli. For times 5200 s, a computer recorded the
times at which stimuli of preset intensities were seen. Later in the
experiment thresholds were obtained by the method of adjustment by
the operator. Thresholds were obtained at 10° in the nasal field on the
horizontal meridian Light intensity was altered by changing both the
intensity of the flashes (1 Hz) and their duration (variable between 1
and 3000 ms).
(including NA) it was 7.891.6 s. Previous workers
have reported that dark adaptation slows in DR: it is
possible that they investigated patients with more
severe disease. However, after 5 min, when diabetic and
normal thresholds were equal, the diabetics’ dark adap-
tation stopped abruptly. Table 1 shows the results.
There is almost no fall of threshold in the diabetics,
while the normal threshold falls 0.8 log. unit. This
difference is highly significant.
4. Discussion
4.1. Abnormalities of dark adaptation in background
DR
Even though we have only investigated a few diabet-
ics, it is clear that in early background DR, with
normal photopic functions, there is a change in rod
dark adapted threshold. The form of the diabetics’ dark
adaptation curve implies that sensitivity is limited by an
‘equivalent background illumination’ [45], 10–30 times
the intensity of the absolute threshold of vision. The
‘equivalent background’ represents either the inability
of the rods to increase their dark current to the maxi-
mum, or a reduction in rod ‘gain’ or a postsynaptic
failure to detect minimal rod signals. Earlier investiga-
tions of dark adaptation in DR are consistent with our
findings [46–48,16–21]. Some of these authors report
slowing of dark adaptation as well as an elevated final
threshold. It is not clear whether this is related to their
different technique or choice of patients. None have
shown that abnormal rod function develops even when
refined test of photopic vision are normal.
We (work in progress) are determining whether this
loss of dark adaptation is reversed by breathing oxygen.
Until then, we cannot directly relate the dark adapted
3.2. Dark adaptation
Fig. 2 shows the dark adaptation curves obtained by
our non standard technique in the normal control
group and in two diabetics. Note the logarithmic time
scale. There is considerable variation in the initial part
of the normal curve. This is partly due to the fact that
the equipment could not change light intensity at suffi-
cient speed to track the rapid increase of sensitivity
which occurs in the first seconds. After 300 s the rate of
dark adaptation slowed so that the method of adjust-
ment could be used. The decline in normal values
continues to \1000 s. The final values reached are
similar to those reported in the literature, for large
fields in the near periphery.
In the diabetics, the initial thresholds were also nor-
mal. Subject NA who had the most advanced condition
had an initial fall of threshold which was one of the
fastest in the entire group. His threshold fell to log
4.8 cd m2 s1 in 3 s. The normal group’s timing
was between 3 and 21 s. There is no significant differ-
ence between the diabetic group and the normals. Thus,
for normals the mean duration for threshold to de-
crease below log4.8 cd m2 s1 was 11.1 s with a
standard deviation of 91.4 s, while for the diabetics
Table 1
Statistical analysis of rod thresholds after 5 and 10 min dark adapta-
tion, in normals and diabetics
Thresholda decreaseThresholdsa
After 5 min After 10 min 5–10 min
Normals
25 25Number 25
0.81*6.74Mean 5.93
S.D. 0.540.740.51
0.1 0.15 0.11S.E.
Diabetics
44Number 4
0.06*6.05Mean 5.99
0.200.44S.D. 0.39
0.110.22 0.20S.E.
a Thresholds in log cd m2 s1 of 440 nm light
* The probability that normals and diabetics come from same popu-
lation (t-test)0.0012
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abnormality to a relative anoxia, related to the in-
creased oxygen demand of rods, though this seems
highly likely. Below we consider other evidence for
retinal hypoxia in dark adaptation, and how hypoxia in
dark adaptation, occurring in the outer retina, could
cause vascular damage in the inner retina.
We anticipated that rod thresholds might reach a
trough, and then rise again in diabetics as hypoxia
developed. This was not seen, probably because (as
recently demonstrated), the change in PO2 caused by
light is nearly as rapid as the electrical activity of the
retina, and too fast to be detected by our technique
[49]. This result is also consistent with ERG findings
which show in background DR that the abnormalities
in the b-wave are much more evident when the provok-
ing flashes are weak [9].
4.2. E6idence that diabetic retina is hypoxic
The success of laser therapy supports this idea. Al-
though it was first thought that laser coagulation
worked by stopping the supply of harmful substances
from pathologically damaged retina [50], in retinal pho-
tocoagulation it is not necessary to direct the laser to
any particular region: it is the reduction in the number
of photoreceptors which seems to be important (though
superficial to the ‘burn’ inner retinal neurones survive,
at least in part). The treatment increases retinal PO2
[51–53].
Additionally, in early DR, ERG abnormalities are
not limited to the photopic oscillatory potentials, gener-
ated in the inner retina [7,8,10]. There are also abnor-
malities in dark adaptation, that suggest loss of
sensitivity and response amplitude of photoreceptors to
dim flashes [9].
Further evidence comes from the discovery that con-
trast sensitivity loss [15] and the loss of Tritan (blue-yel-
low) colour vision in DR [54] (which begins before
ophthalmoscopic changes can be detected) is rapidly
and partially reversed by inhalation of oxygen (but not
air) from a face mask. Tritan vision in normals is
unchanged by breathing oxygen. Colour vision losses
(similar to those of diabetes) occur in normal subjects
after decompression to the equivalent of 12000 ft.,
when the arterial oxygen saturation decreases to about
90%, and are then relieved by oxygen inhalation which
increases the saturation to 95% ([55], Arden and Hogg,
unpublished). The steep S-shaped characteristic of the
Hb:HbO2 saturation curve means that both in normals
under decompression, and in diabetics, the additional
quantity of oxygen carried to the retina by breathing
oxygen is quite small. Therefore, small decrements in
the rate of oxygen supply must cause functional
changes in normals, and be present in early DR. In the
latter, the lack of oxygen occurs under ordinary lighting
conditions, and must thus get worse in dark adaptation.
Finally, direct measurement of PO2 in the ‘clinically’
normal inner retina of long-term diabetic cats revealed
an astonishingly low PO2: in one case 1.7 mmHg,
against the normal 18.5 mmHg [56].
4.3. Is the change in oxygen important?
Since more than half the retinal oxygen supply is
absorbed by rods, and the uptake is rapidly and drasti-
cally reduced by halting the dark current, light adapta-
tion reduces the oxygen requirements by as much as
pan-retinal photocoagulation.
Quite mild degrees of cerebral hypoxia may cause
cerebral symptoms. The maximum safe duration for the
acute exposure of healthy young recruits to the German
Air Force to decompression that affects tritan vision is
deemed to be only 2 h. Even though photoreceptors are
surprisingly resistant to acute anoxia, we have now
confirmed that in cases of DR with normal photopic
and mesopic psychophysics, dark adaptation reveals
loss of scotopic function. Even if this is a protective
mechanism, reducing oxygen consumption by the dia-
betic rod, it must mean that in our patients there is a
unphysiologically low oxygen tension in dark adapta-
tion. The retinal depth at which the greatest DPO2
occurs, is associated with the generation of the b-wave,
which recovers more slowly and incompletely after
anoxia than is the case for the photoreceptors [57].
4.4. How can outer retinal hypoxia cause inner retinal
capillary damage?
The photoreceptor layer is avascular, but a cellular
mechanism for the vascular changes of diabetes is pro-
vided by vascular endothelial growth factor (VEGF)1.
This is produced in the glial (Mueller) cells. The life
time and quantity of its mRNA increases in hypoxia.
VEGF moves from the cell of origin and binds to
receptors on the capillary endothelium, and directly
causes endothelial cell proliferation: it is present in
higher amounts in diabetic retina, and thought to be a
potent and crucial factor stimulating the angiogenic
response in diabetic eyes [58,50]. Any small change
caused by diabetes in capillary walls—for example, the
thickening of basement membranes—could embarrass
retinal oxygen supply to the point where more VEGF
was produced in dark adaptation, and a vicious circle
would then begin to operate. The retinal circulation
would become slightly less adequate, so at the next
period of dark adaptation, the relative hypoxia would
be more profound, and even more VEGF would accu-
mulate: and so on.
1 Since submission of this paper, much work has further implicated
VEGF in DR: e.g. Aiello LP. Vascular Endothelial Growth Factor—
20th century mechanisms, 21st century therapies (minireview). Invest
Ophthalmol Vis Sci 1997;38:1647–52.
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4.5. Under what circumstances in diabetes can dark
adaptation hypoxia alter retinal function?
In the natural history of diabetes, the period between
the onset of functional abnormalities and the worsening
of background retinopathy may be of peculiar signifi-
cance. The large increase in oxygen consumption and
the large change in PO2 in dark adaptation might have
a considerable effect on the progress of the condition.
This would not be the same at all stages of the disease.
At the onset of IDDM diabetes, the only abnormal
stress on the retina is due to uncontrolled glucose
metabolism. If this is corrected, dark adaptation need
not be damaging. In the end stage (e.g. proliferative
retinopathy) there is obvious anoxia. If normal animals
are made hypoxic by respiring them with atmospheres
containing reduced oxygen, the DPO2 between dark and
light is considerably diminished. Therefore, light and
dark adaptation could not cause any change at the end
stages of DR where anoxia is continuous.
4.6. Can possible hypoxic retinal damage be a6oided?
In normals, prolonged dark adaptation occurs each
night and therefore prolonged hypoxia must result.
Even though this has no ill effect, it is difficult to avoid
the conclusion that in DR, where the retina is already
compromised, the oxygen requirements are higher, and
the oxygen tension reduced, dark adaptation for pro-
longed periods is likely to contribute to the develop-
ment of histological changes in the inner retina. It is
possible that continuous exposure to a light intensity of
the ‘equivalent background’ found in these experiments
would be enough to avoid ill effects, and such light
levels are easily achieved through closed lids.
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